Abstract Number: 136 • 2012 ACR/ARHP Annual Meeting
A Delphi Exercise to Identify Characteristic Features of Gout – A Study of Opinions From Patients and Physicians to Inform New Classification Criteria
A Delphi Exercise to Identify Characteristic Features of Gout - a Study of Opinions from Patients and Physicians to Inform New Classification CriteriaBackground/Purpose: Updated classification…Abstract Number: 137 • 2012 ACR/ARHP Annual Meeting
Monosodium Urate Crystals Inhibit Tenocyte Viability and Function: Implications for Periarticular Involvement in Chronic Gout
Background/Purpose: Recent advanced imaging studies have demonstrated that urate deposition in periarticular structures is common in gout. Urate deposition has been observed both adjacent to…Abstract Number: 138 • 2012 ACR/ARHP Annual Meeting
Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout
Background/Purpose: Colchicine is recommended to prevent gout flares in patients initiating and increasing uric acid lowering therapy until serum uric acid is ≤ 6 mg/dL.…Abstract Number: 139 • 2012 ACR/ARHP Annual Meeting
Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout
Background/Purpose: The key to effective long-term management of gout is sustained reduction of serum urate (SU) Methods: Patients with gout and a SU >0.36mmol/L…Abstract Number: 141 • 2012 ACR/ARHP Annual Meeting
Effectiveness of Prophylaxis with Anti-Gout Medications On Risk of Gout Attacks
Background/Purpose: While a few studies have examined colchicine's ability to prevent gout attacks, NSAIDs have not been formally studied in this regard, despite use of…Abstract Number: 142 • 2012 ACR/ARHP Annual Meeting
Efficacy of Canakinumab Versus Triamcinolone Acetonide According to Multiple Gouty Arthritis-Related Health Outcomes Measures
Background/Purpose: Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be a potential therapeutic option for treating acute gout attacks and delaying new attacks…Abstract Number: 143 • 2012 ACR/ARHP Annual Meeting
Proposed Gout Treatment Guidelines and Meeting Serum Urate and Flare Goals
Background/Purpose: Although gout is a relatively common condition, treatment is often not ideal with many patients continuing to experience multiple flares and some developing complications…Abstract Number: 144 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Canakinumab in Patients with Gouty Arthritis
Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits. CAN…Abstract Number: 145 • 2012 ACR/ARHP Annual Meeting
Prevalence of Non-Gout Arthritis in Patients with Gout: Not As Sparing As Previously Thought
Background/Purpose: the presence of other chronic inflammatory disease has been historically and academically thought to be “protective” conditions for the development of gout. Objective: to…Abstract Number: 146 • 2012 ACR/ARHP Annual Meeting
The Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients with Anakinra
Background/Purpose: The management of acute crystal-induced arthritis in the hospital setting may be a difficult clinical problem due to co-morbidities that limit the use of…Abstract Number: 101 • 2012 ACR/ARHP Annual Meeting
Kidney Function and the Risk of Incident Gout in A Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study
Background/Purpose: The 1-year cumulative incidence of gout in patients with new onset end stage renal disease is 5% and rises to 15% by 5 years,…Abstract Number: L02 • ACR Convergence 2023
Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE
Background/Purpose: Endosomal nucleic acid-sensing toll-like receptors 3, 7 and 9 are key innate immune sensors of dsRNA, ssRNA and ssDNA, respectively, whose activities must be…Abstract Number: 0038 • ACR Convergence 2023
Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis
Background/Purpose: Hyperuricemia (HU) is reported as a risk factor for gout and associates with diverse diseases, including ulcerative colitis (UC), while its mechanism remains unclear.…Abstract Number: 0049 • ACR Convergence 2023
Soluble Uric Acid Is an Endogenous Inhibitor of CD38
Background/Purpose: CD38 is the main NAD+-degrading enzyme that plays a key role in innate immunity, aging, cancer, and metabolic disorders. Pharmacological inhibition of CD38 has…Abstract Number: 0055 • ACR Convergence 2023
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
Background/Purpose: Long Interspersed Element-1 (LINE-1) are retrotransposable DNA elements that make up ~17% of the human genome, and their role in health and disease is…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »